Clinical Trial News and Research

RSS

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.

20 Jan 2011

Koronis' KP-1461 drug causes extra mutations to occur in HIV genome in HIV-infected patients

Recently published Phase 2a clinical trial results show that the frequency of specific, drug-induced mutations in the HIV genome can be significantly increased by administering KP-1461, a drug being developed by Koronis Pharmaceuticals based on its novel Viral Decay Acceleration (VDA) drug mechanism.

20 Jan 2011

Boston Scientific announces merger agreement to acquire Atritech

Boston Scientific Corporation today announced the signing of a definitive merger agreement, under which the Company will acquire Atritech, a privately held company based in Plymouth, Minnesota.

19 Jan 2011

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Neogenix Oncology announced today that Dr. Luis Diaz of The Johns Hopkins University Hospital will present data from Ensituximab, the company's novel, therapeutic antibody to treat pancreatic and colorectal cancers. The presentation is scheduled at the American Society of Clinical Oncology (ASCO) 2011 Gastrointestinal Cancers Symposium to be held January 20-22, 2011 at the Moscone Center in San Francisco, CA, USA.

19 Jan 2011

Pisgah to scale-up patent-pending form of hydrocodone

As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.

19 Jan 2011

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

Geron Corporation today announced enrollment of the first patient in a Phase 2 clinical trial to evaluate the activity of the company's telomerase inhibitor drug, imetelstat (GRN163L), in patients with essential thrombocythemia (ET).

19 Jan 2011

Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development

Pluristem Therapeutics, Inc. today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company's planned clinical development program for PLX-PAD.

19 Jan 2011

Concomitant physical symptoms in patients with depression and anxiety associated with poorer prognosis

This study, published in the last 2010 issue of Psychotherapy and Psychosomatics, indicate that concomitant physical symptoms in patients with depression and anxiety are associated with a poorer prognosis of symptoms of depression and anxiety and that it might prove worthwhile to pay attention to the role of multiple physical symptoms in the process of tailoring interventions to meet the needs of depressed and anxious patients in primary care.

19 Jan 2011

Curcumin and dye brilliant blue G may help block dangerous swelling in TBI

An old Indian spice and a dye whose cousin makes sports drinks blue are pointing scientists toward better treatment of traumatic brain injuries.

19 Jan 2011

Almac reports substantial progress in transitioning operations to new headquarters

Almac is making substantial progress in transitioning operations to its new headquarters in Souderton, PA, especially in the area of distribution. The new facility has been successfully shipping clinical trial materials since November, and has recently seen an increase in shipment volumes due to the added efficiencies the new building provides.

19 Jan 2011

Magnetic maneuverable capsule safe and well-tolerated in the stomach

A study from researchers in Germany showed that magnetic maneuvering of a modified capsule endoscope in the stomach of healthy volunteers under clinical conditions is safe, well-tolerated, and technically feasible. Maneuverability of the capsule within the stomach was excellent and visualization of the gastric mucosa, the inner lining of the stomach, was satisfactory in the majority of subjects.

19 Jan 2011

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

Following a successful Phase 1 study for safety, researchers at MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 2 clinical trial testing the ability of a human monoclonal antibody they developed to prevent hepatitis C virus infection of a donor liver in transplant patients.

19 Jan 2011

Medtronic recieves conditional approval from FDA to modify CoreValve U.S. Pivotal Clinical Trial

Medtronic, today announced it has received conditional approval from the U.S. Food and Drug Administration to modify its CoreValve U.S. Pivotal Clinical Trial.

19 Jan 2011

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.11 in the third quarter of fiscal 2011 after taking a charge for a new product licensing fee of $66.1 million or $0.23 per share, net of tax.

18 Jan 2011

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN® versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.

18 Jan 2011

Positive results from Cook Medical's REFORM stent clinical trial for treatment of renal artery stenosis

Study investigators today reported initial data from Cook Medical's REFORM clinical trial that is aimed at assessing the safety and effectiveness of the company's balloon-expandable renal stent for the treatment of renal artery stenosis. The data, presented by Robert Bersin, M.D., at ISET 2011, reveal a nine-month primary patency rate of 89.5 percent and a 97 percent rate of successful delivery and deployment of the stent.

18 Jan 2011

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV

Regeneron and Bayer HealthCare announced initiation of a new Phase 3 clinical trial in collaboration with the Singapore Eye Research Institute investigating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution) in patients with choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia.

18 Jan 2011

Researchers find kidney-specific gene defects may increase risk of heart failure

Scientists have identified the first DNA sequence variant common in the population that is not only associated with an increased risk of heart failure, but appears to play a role in causing it.

18 Jan 2011

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

Diamyd has dosed the first subject in a Phase II clinical trial in the United States evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain.

17 Jan 2011

Advaxis receives DSMB approval to complete dosing in first leg of ADXS11-001 cervical dysplasia clinical trial

The science team from Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, met with the Data Safety Monitoring Board (DSMB), an independent group of medical experts, yesterday and received approval to dose all remaining patients in the initial forty (40) patient leg of the 120-patient, cervical dysplasia clinical trial being conducted in the United States.

14 Jan 2011

Clinical Trial News and Research

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Koronis' KP-1461 drug causes extra mutations to occur in HIV genome in HIV-infected patients

Boston Scientific announces merger agreement to acquire Atritech

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Pisgah to scale-up patent-pending form of hydrocodone

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development

Concomitant physical symptoms in patients with depression and anxiety associated with poorer prognosis

Curcumin and dye brilliant blue G may help block dangerous swelling in TBI

Almac reports substantial progress in transitioning operations to new headquarters

Magnetic maneuverable capsule safe and well-tolerated in the stomach

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

Medtronic recieves conditional approval from FDA to modify CoreValve U.S. Pivotal Clinical Trial

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Positive results from Cook Medical's REFORM stent clinical trial for treatment of renal artery stenosis

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV

Researchers find kidney-specific gene defects may increase risk of heart failure

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

Advaxis receives DSMB approval to complete dosing in first leg of ADXS11-001 cervical dysplasia clinical trial

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News